神农陈宇：房价未见底买房别着急，Ai应用5年内将迎上市潮，中国创新药未来将占全球3成份额

Group 1 - The core viewpoint of the article is that the investment landscape is shifting towards artificial intelligence (AI) applications and innovative pharmaceuticals, with a strong emphasis on the potential of these sectors for future growth [3][4]. - In 2025, the A-share market performed well, largely due to increased policy support for the stock market, with the non-ferrous metals sector being one of the best-performing industries [3]. - The real estate market in Beijing is currently experiencing a downward trend, with rental yields not meeting the industry standard of 3%, suggesting that potential investors should wait before purchasing property [3]. Group 2 - The investment focus for 2026 is on AI applications, which are likened to the real estate investment opportunities of 2006, indicating a significant potential for growth in this sector [4]. - The current investment environment for AI is compared to the early days of the internet, with a strong belief that now is the time to invest in leading AI companies, similar to investing in Tencent in 2004 [4]. - The company has shifted its research focus entirely towards AI applications and AI computing power, abandoning other areas to maximize efficiency and returns [4]. Group 3 - The innovative pharmaceutical sector has been under research since 2016, with significant advancements being made in China, particularly in areas such as dual antibodies, ADC, and cell gene therapy [5]. - The growth of China's innovative pharmaceuticals is expected to follow a long-term cycle, with projections indicating that China could produce 20%-30% of innovative drugs in the next decade [5]. - Data shows a dramatic increase in the outbound business development transactions for innovative drugs, with the total transaction amount rising from $0.9 billion in 2019 to $135.655 billion by the end of 2025, marking a significant growth in both transaction volume and value [5].